FDA Delays Decision On Lilly's Rheumatoid Arthritis Drug Candidate

The FDA's decision on rheumatoid arthritis drug candidate Baricitinib, being developed by Eli Lilly and Co. (LLY) and Incyte Corp. (INCY), has now been postponed by 3 months to April 19, 2017.

from RTT - Biotech http://ift.tt/2jE2SSr
via IFTTT